What Is Your Skin Cancer IQ?

Publication
Article
OncologyONCOLOGY Vol 21 No 6
Volume 21
Issue 6

May is National Skin Cancer Awareness MonthWhat Is Your Skin Cancer IQ?Identifying BCC, SCC, and melanoma

 
Basal Cell Carcinoma (BCC)
Squamous Cell Carcinoma (SCC)
Melanoma

Appearance

Small, shiny bumps or nodules that are red, pink, or white; persistent, nonhealing sore; reddish flat patch; or a scar-like white or yellowish area
Red, scaly patches or bumps
Asymmetrical, mottled patches with notched or blurred borders, typically in tan, brown, or black
Size
Takes many years or months to reach a half-inch
Can reach up to three-quarters of an inch to an inch
Usually greater than 6 mm
Location
Head, neck, hands, and occasionally on the trunk of the body
Face, ears, neck, lips, and back of the hands
Can occur anywhere on the body, most frequently on the upper back or legs, as well as the head and neck
Progression
Grows slowly and may bleed, crust over, then the cycle repeats
Can develop into large masses
Can appear without warning, or may begin in or near a mole or other dark spot on the skin
Potential for metastasis
Rare, but can grow into nearby areas and may invade bone and vital structures, such as the eye
Can metastasize, and may be fatal if not treated
Can metastasize, and is deadly if not treated
Prevalence
BCC accounts for 80% of all skin cancers (more than 800,000 new cases each year).
SCC accounts for 16% of all skin cancers (approximately 250,000 new cases each year). About 2,500 deaths from SCC are expected during 2007.
Melanoma accounts for 4% of all skin cancers (approximately 59,940 new cases each year). More than 8,110 melanoma deaths are expected during 2007.

Adapted, with permission, from the American Academy of Dermatology’s “Actinic Keratoses and Skin Cancer,” available at http://www.aad.org/public/News/DermInfo/DInfoSkinCancerUpdates.htm.

Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Related Content